Histological classification and molecular genetics of meningiomas

CBTRUS (2005). Statistical report: primary brain tumors in the United States, 1998–2002. Central Brain Tumor Registry of the United States. Jaaskelainen, 1986, Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy, and outcome, Surg Neurol, 25, 233, 10.1016/0090-3019(86)90233-8 Sheporaitis, 1992, Intracranial meningioma, AJNR Am J Neuroradiol, 13, 29 Harrison, 1991, Radiation-induced meningiomas: experience at the Mount Sinai Hospital and review of the literature, J Neurosurg, 75, 564, 10.3171/jns.1991.75.4.0564 Bickerstaff, 1958, The relapsing course of certain meningiomas in relation to pregnancy and menstruation, J Neurol Neurosurg Psychiatry, 21, 89, 10.1136/jnnp.21.2.89 Baser, 2003, Neurofibromatosis 2, Curr Opin Neurol, 16, 27, 10.1097/00019052-200302000-00004 Louis, 1995, Neuropathology and molecular genetics of neurofibromatosis 2 and related tumors, Brain Pathol, 5, 163, 10.1111/j.1750-3639.1995.tb00590.x Louis, 1995, Hereditary tumor syndromes of the nervous system: overview and rare syndromes, Brain Pathol, 5, 145, 10.1111/j.1750-3639.1995.tb00588.x Asgharian, 2004, Meningiomas may be a component tumor of multiple endocrine neoplasia type 1, Clin Cancer Res, 10, 869, 10.1158/1078-0432.CCR-0938-3 Kleihues, 2000 Wellenreuther, 1995, Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma, Am J Pathol, 146, 827 Hartmann, 2006, NF2 mutations in secretory and other rare variants of meningiomas, Brain Pathol, 16, 15, 10.1111/j.1750-3639.2006.tb00557.x Perry, 1999, “Malignancy” in meningiomas: a clinicopathologic study of 116 patients, with grading implications, Cancer, 85, 2046 Weber, 1997, Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression, Proc Natl Acad Sci USA, 94, 14719, 10.1073/pnas.94.26.14719 Perry, 1997, Meningioma grading: an analysis of histologic parameters, Am J Surg Pathol, 21, 1455, 10.1097/00000478-199712000-00008 Zorludemir, 1995, Clear cell meningioma. A clinicopathologic study of a potentially aggressive variant of meningioma, Am J Surg Pathol, 19, 493, 10.1097/00000478-199505000-00001 Couce, 2000, Chordoid meningioma: a clinicopathologic study of 42 cases, Am J Surg Pathol, 24, 899, 10.1097/00000478-200007000-00001 Steilen-Gimbel, 1999, Unbalanced translocation t(1;3)(p12–13;q11) in meningiomas as the unique feature of chordoid differentiation, Genes Chromosomes Cancer, 26, 270, 10.1002/(SICI)1098-2264(199911)26:3<270::AID-GCC14>3.0.CO;2-W Paulus, 1993, Effect of embolisation of meningioma on Ki-67 proliferation index, J Clin Pathol, 46, 876, 10.1136/jcp.46.9.876 Ludwin, 1975, Papillary meningioma: a malignant variant of meningioma, Cancer, 36, 1363, 10.1002/1097-0142(197510)36:4<1363::AID-CNCR2820360427>3.0.CO;2-Z Pasquier, 1986, Papillary meningioma: clinicopathologic study of seven cases and review of the literature, Cancer, 58, 299, 10.1002/1097-0142(19860715)58:2<299::AID-CNCR2820580215>3.0.CO;2-W Kepes, 1998, Rhabdoid transformation of tumor cells in meningiomas: a histologic indication of increased proliferative activity: report of four cases, Am J Surg Pathol, 22, 231, 10.1097/00000478-199802000-00012 Perry, 1998, “Rhabdoid” meningioma: an aggressive variant, Am J Surg Pathol, 22, 1482, 10.1097/00000478-199812000-00005 Schnitt, 1986, Meningiomas. Diagnostic value of immunoperoxidase staining for epithelial membrane antigen, Am J Surg Pathol, 10, 640, 10.1097/00000478-198609000-00006 Artlich, 1990, Immunohistochemical profile of meningiomas and their histological subtypes, Hum Pathol, 21, 843, 10.1016/0046-8177(90)90054-9 Nakasu, 2001, Significance of MIB-1 staining indices in meningiomas: comparison of two counting methods, Am J Surg Pathol, 25, 472, 10.1097/00000478-200104000-00006 Perry, 1998, The prognostic significance of MIB-1, p53, and DNA flow cytometry in completely resected primary meningiomas, Cancer, 82, 2262, 10.1002/(SICI)1097-0142(19980601)82:11<2262::AID-CNCR23>3.0.CO;2-R Carroll, 1993, Progesterone receptor expression in meningiomas, Cancer Res, 53, 1312 Hsu, 1997, Progesterone and estrogen receptors in meningiomas: prognostic considerations, J Neurosurg, 86, 113, 10.3171/jns.1997.86.1.0113 Perry, 2000, Merlin, DAL-1, and progesterone receptor expression in clinicopathologic subsets of meningioma: a correlative immunohistochemical study of 175 cases, J Neuropathol Exp Neurol, 59, 872, 10.1093/jnen/59.10.872 Ribalta, 2004, The mitosis-specific antibody anti-phosphohistone-H3 (PHH3) facilitates rapid reliable grading of meningiomas according to WHO 2000 criteria, Am J Surg Pathol, 28, 1532, 10.1097/01.pas.0000141389.06925.d5 Zang, 2001, Meningioma: a cytogenetic model of a complex benign human tumor, including data on 394 karyotyped cases, Cytogenet Cell Genet, 93, 207, 10.1159/000056986 Seizinger, 1987, Molecular genetic approach to human meningioma: loss of genes on chromosome 22, Proc Natl Acad Sci USA, 84, 5419, 10.1073/pnas.84.15.5419 Dumanski, 1987, Deletion mapping of a locus on human chromosome 22 involved in the oncogenesis of meningioma, Proc Natl Acad Sci USA, 84, 9275, 10.1073/pnas.84.24.9275 Harada, 1996, Molecular genetic investigation of the neurofibromatosis type 2 tumor suppressor gene in sporadic meningioma, J Neurosurg, 84, 847, 10.3171/jns.1996.84.5.0847 Ruttledge, 1994, Deletions on chromosome 22 in sporadic meningioma, Genes Chromosomes Cancer, 10, 122, 10.1002/gcc.2870100207 Leone, 1999, NF2 gene mutations and allelic status of 1p, 14q and 22q in sporadic meningiomas, Oncogene, 18, 2231, 10.1038/sj.onc.1202531 Merel, 1995, Predominant occurrence of somatic mutations of the NF2 gene in meningiomas and schwannomas, Genes Chromosomes Cancer, 13, 211, 10.1002/gcc.2870130311 Lomas, 2005, Genetic and epigenetic alteration of the NF2 gene in sporadic meningiomas, Genes Chromosomes Cancer, 42, 314, 10.1002/gcc.20141 Gusella, 1999, Merlin: the neurofibromatosis 2 tumor suppressor, Biochim Biophys Acta, 1423, M29 Trofatter, 1993, A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor, Cell, 72, 791, 10.1016/0092-8674(93)90406-G Rouleau, 1993, Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2, Nature, 363, 515, 10.1038/363515a0 Shimizu, 2002, Structural basis for neurofibromatosis type 2: crystal structure of the merlin FERM domain, J Biol Chem, 277, 10332, 10.1074/jbc.M109979200 Kang, 2002, The structure of the FERM domain of merlin, the neurofibromatosis type 2 gene product, Acta Crystallogr D Biol Crystallogr, 58, 381, 10.1107/S0907444901021175 Obremski, 1998, Merlin, the neurofibromatosis type 2 gene product, and beta1 integrin associate in isolated and differentiating Schwann cells, J Neurobiol, 37, 487, 10.1002/(SICI)1097-4695(199812)37:4<487::AID-NEU1>3.0.CO;2-B Morrison, 2001, The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44, Genes Dev, 15, 968, 10.1101/gad.189601 Scoles, 1998, Neurofibromatosis 2 tumour suppressor schwannomin interacts with betaII-spectrin, Nat Genet, 18, 354, 10.1038/ng0498-354 James, 2001, The neurofibromatosis 2 protein product merlin selectively binds F-actin but not G-actin, and stabilizes the filaments through a lateral association, Biochem J, 356, 377, 10.1042/0264-6021:3560377 Jannatipour, 2001, Schwannomin isoform-1 interacts with syntenin via PDZ domains, J Biol Chem, 276, 33093, 10.1074/jbc.M105792200 Xu, 1998, Merlin differentially associates with the microtubule and actin cytoskeleton, J Neurosci Res, 51, 403, 10.1002/(SICI)1097-4547(19980201)51:3<403::AID-JNR13>3.0.CO;2-7 Murthy, 1998, NHE-RF, a regulatory cofactor for Na(+)-H+ exchange, is a common interactor for merlin and ERM (MERM) proteins, J Biol Chem, 273, 1273, 10.1074/jbc.273.3.1273 Gutmann, 2001, The NF2 interactor, hepatocyte growth factor-regulated tyrosine kinase substrate (HRS), associates with merlin in the “open” conformation and suppresses cell growth and motility, Hum Mol Genet, 10, 825, 10.1093/hmg/10.8.825 Sherman, 2001, Merlin: hanging tumor suppression on the Rac, Trends Cell Biol, 11, 442, 10.1016/S0962-8924(01)81334-9 Kissil, 2002, Merlin phosphorylation by p21-activated kinase 2 and effects of phosphorylation on merlin localization, J Biol Chem, 277, 10394, 10.1074/jbc.M200083200 Shaw, 2001, The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling, Dev Cell, 1, 63, 10.1016/S1534-5807(01)00009-0 Xiao, 2002, p21-activated kinase links Rac/Cdc42 signaling to merlin, J Biol Chem, 277, 883, 10.1074/jbc.C100553200 Fernandez-Valle, 2002, Paxillin binds schwannomin and regulates its density-dependent localization and effect on cell morphology, Nat Genet, 31, 354, 10.1038/ng930 Gutmann, 2000, Loss of DAL-1, a protein 4.1-related tumor suppressor, is an important early event in the pathogenesis of meningiomas, Hum Mol Genet, 9, 1495, 10.1093/hmg/9.10.1495 Nunes, 2005, Inactivation patterns of NF2 and DAL-1/4.1B (EPB41L3) in sporadic meningioma, Cancer Genet Cytogenet, 162, 135, 10.1016/j.cancergencyto.2005.04.003 Martinez-Glez, 2005, Mutational analysis of the DAL-1/4.1B tumour-suppressor gene locus in meningiomas, Int J Mol Med, 16, 771 Heinrich, 2003, Multiple meningiomas: Investigating the molecular basis of sporadic and familial forms, Int J Cancer, 103, 483, 10.1002/ijc.10840 Gerber, 2006, Protein 4.1B/differentially expressed in adenocarcinoma of the lung-1 functions as a growth suppressor in meningioma cells by activating Rac1-dependent c-Jun-NH(2)-kinase signaling, Cancer Res, 66, 5295, 10.1158/0008-5472.CAN-05-1628 Surace, 2004, Loss of tumor suppressor in lung cancer-1 (TSLC1) expression in meningioma correlates with increased malignancy grade and reduced patient survival, J Neuropathol Exp Neurol, 63, 1015, 10.1093/jnen/63.10.1015 Robb, 2003, Identification of a third Protein 4.1 tumor suppressor, Protein 4.1R, in meningioma pathogenesis, Neurobiol Dis, 13, 191, 10.1016/S0969-9961(03)00071-8 Lomas, 2002, Loss of chromosome 22 and absence of NF2 gene mutation in a case of multiple meningiomas, Hum Pathol, 33, 375, 10.1053/hupa.2002.32229 Peyrard, 1994, Characterization of a new member of the human beta-adaptin gene family from chromosome 22q12, a candidate meningioma gene, Hum Mol Genet, 3, 1393, 10.1093/hmg/3.8.1393 Peyrard, 1996, Structure of the promoter and genomic organization of the human beta'-adaptin gene (BAM22) from chromosome 22q12, Genomics, 36, 112, 10.1006/geno.1996.0431 Lekanne Deprez, 1995, Cloning and characterization of MN1, a gene from chromosome 22q11, which is disrupted by a balanced translocation in a meningioma, Oncogene, 10, 1521 Peyrard, 1999, The human LARGE gene from 22q12.3–q13.1 is a new, distinct member of the glycosyltransferase gene family, Proc Natl Acad Sci USA, 96, 598, 10.1073/pnas.96.2.598 Schmitz, 2001, INI1 mutations in meningiomas at a potential hotspot in exon 9, Br J Cancer, 84, 199, 10.1054/bjoc.2000.1583 Buschges, 2002, Allelic gain and amplification on the long arm of chromosome 17 in anaplastic meningiomas, Brain Pathol, 12, 145, 10.1111/j.1750-3639.2002.tb00429.x Lamszus, 1999, Allelic losses at 1p, 9q, 10q, 14q, and 22q in the progression of aggressive meningiomas and undifferentiated meningeal sarcomas, Cancer Genet Cytogenet, 110, 103, 10.1016/S0165-4608(98)00209-X Ozaki, 1999, Comparative genomic hybridization analysis of genetic alterations associated with malignant progression of meningioma, J Neurooncol, 41, 167, 10.1023/A:1006086723607 Bello, 2000, High-resolution analysis of chromosome arm 1p alterations in meningioma, Cancer Genet Cytogenet, 120, 30, 10.1016/S0165-4608(99)00249-6 Sulman, 2004, Genomic annotation of the meningioma tumor suppressor locus on chromosome 1p34, Oncogene, 23, 1014, 10.1038/sj.onc.1206623 Murakami, 2003, A consistent region of deletion on 1p36 in meningiomas: identification and relation to malignant progression, Cancer Genet Cytogenet, 140, 99, 10.1016/S0165-4608(02)00653-2 Lomas, 2001, Analysis of p73 gene in meningiomas with deletion at 1p, Cancer Genet Cytogenet, 129, 88, 10.1016/S0165-4608(01)00430-7 Bostrom, 2001, Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas, Am J Pathol, 159, 661, 10.1016/S0002-9440(10)61737-3 Mendiola, 1999, Search for mutations of the hRAD54 gene in sporadic meningiomas with deletion at 1p32, Mol Carcinog, 24, 300, 10.1002/(SICI)1098-2744(199904)24:4<300::AID-MC8>3.0.CO;2-G Niedermayer, 1997, Loss of alkaline phosphatase activity in meningiomas: a rapid histochemical technique indicating progression-associated deletion of a putative tumor suppressor gene on the distal part of the short arm of chromosome 1, J Neuropathol Exp Neurol, 56, 879, 10.1097/00005072-199708000-00006 Bello, 2004, DNA methylation of multiple promoter-associated CpG islands in meningiomas: relationship with the allelic status at 1p and 22q, Acta Neuropathol (Berl), 108, 413, 10.1007/s00401-004-0911-6 Lomas, 2004, Methylation status of TP73 in meningiomas, Cancer Genet Cytogenet, 148, 148, 10.1016/S0165-4608(03)00244-9 Ruas, 1998, The p16INK4a/CDKN2A tumor suppressor and its relatives, Biochim Biophys Acta, 1378, F115 Prives, 1999, The p53 pathway, J Pathol, 187, 112, 10.1002/(SICI)1096-9896(199901)187:1<112::AID-PATH250>3.0.CO;2-3 Perry, 2002, A role for chromosome 9p21 deletions in the malignant progression of meningiomas and the prognosis of anaplastic meningiomas, Brain Pathol, 12, 183, 10.1111/j.1750-3639.2002.tb00433.x Peters, 1998, Analysis of the PTEN gene in human meningiomas, Neuropathol Appl Neurobiol, 24, 3, 10.1046/j.1365-2990.1998.00093.x Wang, 1995, Detection of TP53 gene mutation in human meningiomas: a study using immunohistochemistry, polymerase chain reaction/single-strand conformation polymorphism and DNA sequencing techniques on paraffin-embedded samples, Int J Cancer, 64, 223, 10.1002/ijc.2910640402 Cai, 2001, PS6K amplification characterizes a small subset of anaplastic meningiomas, Am J Clin Pathol, 115, 213, 10.1309/FVNU-7UBY-DXE3-77MT Nutt, 2003, Gene expression-based classification of malignant gliomas correlates better with survival than histological classification, Cancer Res, 63, 1602 Wrobel, 2005, Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression, Int J Cancer, 114, 249, 10.1002/ijc.20733 Watson, 2002, Molecular characterization of human meningiomas by gene expression profiling using high-density oligonucleotide microarrays, Am J Pathol, 161, 665, 10.1016/S0002-9440(10)64222-8 Lusis, 2005, Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma, Cancer Res, 65, 7121, 10.1158/0008-5472.CAN-05-0043 Kalala, 2005, The hTERT protein as a marker for malignancy in meningiomas, Oncol Rep, 13, 273 Leuraud, 2004, Prognostic value of allelic losses and telomerase activity in meningiomas, J Neurosurg, 100, 303, 10.3171/jns.2004.100.2.0303 Simon, 2001, Alterations of INK4a(p16-p14ARF)/INK4b(p15) expression and telomerase activation in meningioma progression, J Neurooncol, 55, 149, 10.1023/A:1013863630293 Maes, 2005, The hTERT-protein and Ki-67 labelling index in recurrent and non-recurrent meningiomas, Cell Prolif, 38, 3, 10.1111/j.1365-2184.2005.00325.x Nevins, 2001, The Rb/E2F pathway and cancer, Hum Mol Genet, 10, 699, 10.1093/hmg/10.7.699 Bates, 1998, p14ARF links the tumour suppressors RB and p53, Nature, 395, 124, 10.1038/25867 Cuevas, 2005, Meningioma transcript profiles reveal deregulated Notch signaling pathway, Cancer Res, 65, 5070, 10.1158/0008-5472.CAN-05-0240 Nordqvist, 1997, A high ratio of insulin-like growth factor II/insulin-like growth factor binding protein 2 messenger RNA as a marker for anaplasia in meningiomas, Cancer Res, 57, 2611 Nordqvist, 2002, Expression of IGF-II, IGFBP-2, -5, and -6 in meningiomas with different brain invasiveness, J Neurooncol, 57, 19, 10.1023/A:1015765613544 Johnson, 1994, The epidermal growth factor receptor is associated with phospholipase C-gamma 1 in meningiomas, Hum Pathol, 25, 146, 10.1016/0046-8177(94)90270-4 Jones, 1990, Epidermal growth factor receptor expression in 72 meningiomas, Cancer, 66, 152, 10.1002/1097-0142(19900701)66:1<152::AID-CNCR2820660127>3.0.CO;2-5 Weisman, 1987, Characterization of the epidermal growth factor receptor in human meningioma, Cancer Res, 47, 2172 Carroll, 1997, Expression and activation of epidermal growth factor receptors in meningiomas, J Neurosurg, 87, 315, 10.3171/jns.1997.87.2.0315 Hsu, 1998, MIB-1 (Ki-67) index and transforming growth factor-alpha (TGF alpha) immunoreactivity are significant prognostic predictors for meningiomas, Neuropathol Appl Neurobiol, 24, 441, 10.1046/j.1365-2990.1998.00150.x Linggood, 1995, TGF alpha expression in meningioma—tumor progression and therapeutic response, J Neurooncol, 26, 45, 10.1007/BF01054768 Shamah, 1997, Detection of activated platelet-derived growth factor receptors in human meningioma, Cancer Res, 57, 4141 Todo, 1996, Autocrine growth stimulation of human meningioma cells by platelet-derived growth factor, J Neurosurg, 84, 852, 10.3171/jns.1996.84.5.0852 Adams, 1991, Autocrine control of human meningioma proliferation: secretion of platelet-derived growth-factor-like molecules, Int J Cancer, 49, 398, 10.1002/ijc.2910490315 Puduvalli, 2005, Induction of apoptosis in primary meningioma cultures by fenretinide, Cancer Res, 65, 1547, 10.1158/0008-5472.CAN-04-0786 Lee, 1990, Characterization of a newly established malignant meningioma cell line of the human brain: IOMM-Lee, Neurosurgery, 27, 389, 10.1227/00006123-199009000-00008 Baia, 2006, A genetic strategy to overcome the senescence of primary meningioma cell cultures, J Neurooncol, 78, 113, 10.1007/s11060-005-9076-y Puttmann, 2005, Establishment of a benign meningioma cell line by hTERT-mediated immortalization, Lab Invest, 85, 1163, 10.1038/labinvest.3700307 Kalamarides, 2002, Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse, Genes Dev, 16, 1060, 10.1101/gad.226302 Gutmann, 2002, Mouse models of neurofibromatosis 1 and 2, Neoplasia, 4, 279, 10.1038/sj.neo.7900249